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BH3-mimetics are small molecule inhibitors that neutralize the function of anti-apoptotic BCL-2 family 
members. BH3-mimetics have recently gained a lot of popularity in oncology because of their success 
in cancer treatment. However, BH3-mimetics might have a broader clinical application. Here, we 
established an ex vivo flow cytometric assay allowing the comparison of the impact of BH3-mimetics 
(ABT-199, ABT-263, WEHI-539, and S63845) on leukocyte populations of both, healthy human subjects 
and C57BL/6 J wild type mice. BH3-mimetics were added to freshly drawn blood that was diluted 
1/2 in cell medium, and BH3-mimetics-mediated impact on leukocyte count was assessed by flow 
cytometry. Our results demonstrate that responses towards 1μM of BH3-mimetics can be identical as 
well as considerably different in leukocytes of humans and mice. For instance, the inhibition of BCL-2 
by ABT-199 caused cell death in all types of lymphocytes in mice but was exclusively specific for B 
cells in humans. Moreover, inhibition of BCL-XL by WEHI-539 affected solely mouse leukocytes while 
targeting MCL-1 by S63845 resulted in efficient induction of cell death in human neutrophils but not in 
their mouse counterparts. Our ex vivo assay enables initial identification of analogies and differences 
between human and mouse leukocytes in response towards BH3-mimetics.
Excessive cell death or evasion from apoptosis is associated with the development of autoimmune disorders or 
cancer1. Apoptosis is primarily regulated by B cell lymphoma 2 (BCL-2) family members, which differ based on 
their ability to promote or to suppress apoptosis by affecting the integrity of the mitochondrial outer membrane 
(MOM). Anti-apoptotic BCL-2 family members (BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1/A1) function by inhib-
iting their pro-apoptotic counterparts, which, upon their “unleashing“, trigger MOM permeabilization followed 
by activation of apoptotic caspases, culminating in the ultimate, irreversible cascade towards cellular demise2,3. 
Previous studies have shown that the interplay of pro- and anti-apoptotic BCL-2 members specifically regu-
lates hematopoiesis and survival of leukocytes in blood and bone marrow4,5. Importantly, upregulation of certain 
anti-apoptotic BCL-2 family members, such as BCL-2, B cell lymphoma-extra-large (BCL-XL), and myeloid cell 
leukemia (MCL-1), are also known to support development and survival of cancerous cells as well as evasion 
from cancer therapy6. To overcome such resistance towards apoptosis, small molecule inhibitors called BCL-2 
homology domain 3 (BH3) -mimetics have been developed to specifically neutralize anti-apoptotic BCL-2 family 
members in order to restore normal apoptotic signaling in cancerous cells7.
Most studies involving BH3-mimetics have been carried out in cancer cells. However, with some exceptions, 
the impact of these compounds on key leukocyte populations from healthy individuals is less clear. As the expres-
sion of individual anti-apoptotic BCL-2 family members varies substantially between different leukocyte subtypes 
and their activation statuses, BH3-mimetics may also represent a powerful tool to target specific cell types in 
diseases other than cancer, for example in immune disorders. In this study, we present a flow cytometry assay that 
allows tracking changes in the major myeloid and lymphoid cell populations ex vivo using whole blood samples. 
We established an assay valid for both human and mouse derived blood samples, allowing an initial comparison 
of the response of human and mouse leukocytes towards BH3-mimetics.
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Results and Discussion
In this study, we present an ex vivo flow cytometry assay that allows quantitative assessment of human and mouse 
leukocyte viabilities in whole blood samples in response to BH3-mimetics. We used following BH3-mimetics: 
ABT-199 (BCL-2 inhibitor), ABT-263 (inhibiting BCL-2, BCL-XL, and BCL-W), WEHI-539 (targeting BCL-XL), 
and S63845 (MCL-1 inhibitor).
We aimed to establish an assay to test the effects of BH3-mimetics in human and mouse specimens under 
non-invasive conditions, which are nevertheless close to physiological conditions. Ex vivo conditions using whole 
blood samples provide such a potential. In order to minimize the impact of pre-analytic factors, we first compared 
the effect of different anticoagulants on cellular integrity over different time points. We observed that in unfrac-
tionated blood cellular integrity is not maintained long enough to test the effect of BH3-mimetics, regardless of 
the type of anticoagulant used (data not shown). Therefore, and based on our experience with routine testing of 
patient’s samples, we diluted whole blood samples 1/2 in complete RPMI +/+ cell medium. We observed that 
in diluted human whole blood samples a portion of the granulocyte population (as identified based on high side 
scatter) shifted towards the debris section within 6 hours and almost completely lost its initial integrity within 
24 hours (Fig. 1a, circle) if ethylenediaminetetraacetic acid (EDTA) was used. However, this effect was negli-
gible in lithium heparin (LiHep) samples. Regardless of the anticoagulant used, human monocytes started to 
vanish after 16 hours, based on the decrease of the CD14 positive population (see Supplementary Fig. S5). In 
mouse blood, EDTA and LiHep preparations were comparable, but leukocytes were overall more ephemeral 
compared to their human counterparts. For the analysis of BH3-mimetics-mediated cell death we intended to use 
an incubation time that was long enough to detect an effect of BH3-mimetics and that had only a minimal effect 
on spontaneous cell death. Our previous study has shown that at least 8 hours and ideally, more than 10 hours 
were necessary to induce significant cell death in human granulocytes8. Compared to fresh LiHep samples (0 h), 
8 hours for both human and mouse samples and 16 hours for human samples showed the smallest bias of sponta-
neous cell death. Hence, we decided to expose LiHep blood samples for 8 hours (mouse and human) and 16 hours 
(only human), respectively.
In order to compare the maximum cell inducing effect of BH3-mimetics irrespective of dose, all compounds 
were used at 1 µM. This concentration was selected based on previous results obtained from in vitro differentiated 
basophils9 and on other studies demonstrating that 1 µM does not induce cellular toxicity10. We confirmed that 
specific inhibition of BCL-2 by ABT-199 during 8 hours elicited a significant decrease in human and mouse B cell 
numbers, whereby the effect was more pronounced in human B cells (compare Fig. 2a,b) and which was further 
enhanced if human blood samples were exposed to ABT-199 during 16 hours (see Supplementary Fig. S6). In 
accordance with studies by others11,12, our data corroborated that mouse T, NK, and NKT cells are highly sus-
ceptible to BCL-2 inhibition (Fig. 2b). In contrast, human T, NK, and NKT cells were only affected if exposed for 
16 hours (see Supplementary Fig. S6) but not if incubated for 8 hours (Fig. 2a).
In order to evaluate whether the expression levels of the respective targets reflect the sensitivity towards 
BH3-mimetics, we analyzed the expression of BCL-2 (see Supplementary Fig. S7), upon the inhibition of which 
prominent differences within and between human and mouse lymphocytes were seen. In order to make a com-
parison of human and mouse samples possible, we determined absolute BCL-2 molecules per cells by using 
a commercially available standard consisting of 5 different bead populations. That approach prevents biases 
due to different instrument settings, compensation and autofluorescence between human and mouse samples. 
Absolute quantification of BCL-2 molecules per cell revealed that in mouse lymphocytes the higher the level 
of BCL-2 expression was (NKT > NK = T cells > B cells) (Fig. 3b) the more sensitive they were towards BCL-2 
inhibition (NKT = NK = T cells > B cells). Interestingly, human T and NKT cells express up to 10-fold higher 
levels of BCL-2 than their mouse counterpart (Fig. 3a,b). This species-specific difference in expression of BCL-2 
could explain why BCL-2 inhibition was only effective after 16 hours in human cells (see Supplementary Fig. S6), 
whereas in mouse samples 8 hours were sufficient (Fig. 2b). However, the sensitivity towards ABT-199 cannot 
in all instances be explained by the expression level of its target. For instance, human B cells express BCL-2 at 
comparable levels as human T cells of which the latter showed low sensitivity towards ABT-199 treatment. Our 
findings support the widely accepted view that that the sensitivity towards BH3-mimetics is most probably the 
sum of the interplay of a network of anti- and pro-apoptotic BCL-2 family members.
We have previously published that ABT-199 potently induces apoptosis in mouse basophils and mast cells9 
as well as in human basophils, but not in human eosinophils or neutrophils8. Our present data confirmed that 
survival of both human and mouse blood basophils was highly dependent on BCL-2, although with different time 
dependency. While the numbers of mouse basophils decreased by about 50% in response to ABT-199 treatment 
at 8 hours already (Fig. 2b) a 50% reduction of human basophils was observed after 16 hours (Fig. 2a and see 
Supplementary Fig. S6). Nevertheless, this is an interesting result as basophils are associated with inflammatory 
response in various allergic disorders13–15. Therefore, targeting basophils using ABT-199 could be an attractive 
approach to modulate the outcome of allergic inflammation, considering the fact that after prolonged incuba-
tion time of 24 hours, the half-maximal effective concentration of ABT-199 is up to 140-times lower in human 
basophils than B cells8,11. Human neutrophils and eosinophils were not affected by ABT-199 (Fig. 2a), which is in 
agreement with our former findings8.
ABT-263 was a less effective inducer of cell death than ABT-199, affecting significantly human B cells, and 
basophils but only if exposed longer than 16 hours (Fig. 2c, and see Supplementary Fig. S6). The impact of ABT-
263 on leukocyte survival under ex vivo conditions at later time points could not be tested in mouse samples, 
since after 8 hours the cellular integrity seemed not to be guaranteed anymore (Fig. 1b). Moreover, our previously 
published studies demonstrated that ABT-263 also greatly accelerated spontaneous apoptosis of isolated human 
eosinophils8 and mouse basophils9. We assume that a higher concentration of ABT-263 and/or a longer incuba-
tion time would be required to achieve a similar response as ABT-199 in human eosinophils and mouse basophils 
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for two reasons. On the one hand, it has been reported that ABT-263 exhibits reduced activity when exposed to 
plasma proteins16 and on the other hand it has a 100 times lower inhibitory constant to BCL-2 than ABT-199 17,18.
In contrast to human leukocytes and mouse T, NK and NKT, which were not responsive to WEHI-539 
(Fig. 1e,f), selective inhibition of BCL-XL was effective at killing mouse cells of the myeloid lineage, including 
basophils, eosinophils and DCs (Fig. 2f). The importance of BCL-XL for the survival of mouse but not human 
basophils (see Supplementary Fig. S8) is consistent with our previous work using isolated basophils9.
The newly developed MCL-1 selective inhibitor S63845 has drawn a lot of attention as MCL-1 emerges as a 
critical player in conferring chemoresistance, underlined by the frequent amplification of the MCL-1 gene in a 
variety of human cancers19. While none of the mouse leukocyte populations were affected by 1μM S63845, the 
Figure 1. Evaluation of the effect of EDTA and lithium heparin on human and mouse blood ex vivo culture 
conditions. Shown are the light scatter characteristics of human (a) and mouse (b) blood samples collected in 
either EDTA or LiHep blood collection tubes, as indicated. Blood samples were diluted 1/2 in cell culturing 
medium (RPMI+/+) and kept at 37 °C in a 5% CO2 atmosphere for 6, 8, 16 and 24 hours. Fresh blood samples 
(0 h) were processed immediately after blood sampling.
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Figure 2. Effect of different BH3-mimetics on the main leukocyte populations in mouse and human whole 
blood samples. Shown are the effect of ABT-199, ABT-263, WEHI-539, and S63845 on total cell count of 
major leukocyte subpopulations in human (a,c,e,g) and mouse (b,d,f,h) blood samples. Mouse and human 
blood samples were kept under ex vivo culture conditions for 8 hours. All BH3-mimetics were used at a final 
concentration of 1 µM. The cell count of a given cell type in the untreated sample (dotted line) was used as a 
reference for normalization of the treatment groups. A total of 4 biological replicates are shown for each species. 
Ordinary one-way ANOVA followed by Dunnett’s posthoc test was used for comparing control and treatment 
groups for statistical differences. Data are shown as mean (SD). n.s. (not significant); *P < 0.05; **P < 0.01, 
***P < 0.001, ****P < 0.0001.
5Scientific RepoRtS |          (2020) 10:222  | https://doi.org/10.1038/s41598-019-57000-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
number of human neutrophils decreased within 8 hours by over 50% in response to S63845 (Fig. 2g,h), which 
might be explained by the higher affinity of S63845 towards human MCL-1 compared to mouse MCL-120. 
Moreover, a recently published study demonstrated that up to 10μM of S63845 are needed to induce significant 
cell death in short-termed murine AML cell lines21. Hence, we assume that higher concentration of S63845 is 
needed to efficiently trigger cell death in mouse leukocytes. The susceptibility of human neutrophils to S63845 
was anticipated as survival of this cell types has been linked to MCL-122. Moreover, and in line with a former study 
showing that peripheral blood B cell survival correlates with MCL-1 levels23, our data - albeit not statistically sig-
nificant – demonstrate that human B cell numbers fell by over 25% within 16 hours upon MCL-1 antagonism (see 
Supplementary Fig. S6).
Our ex vivo flow cytometry approach showed that inhibition of essential anti-apoptotic proteins differently 
impacts the absolute cell count of major leukocyte populations circulating in venous blood of humans and 
mice, whereby ABT-199 and WEHI-539 treatment groups exhibited the statistically most significant differences 
after 8 hours incubation (see Supplementary Fig. S8). Our data underline that the effect of BH3-mimetics differ 
between human and mouse leukocytes. It remains to be tested whether strain-to-strain differences exist in the 
mouse; however, the extrapolation from mouse-derived data to the human needs to be critically examined.
Materials and Methods
Blood withdrawal. This study has been approved by the Ethics Committee of the canton of Bern (Kantonale 
Ethikkomission Bern; Nr. 2016-01571) and was conducted according to the criteria set by the declaration of 
Helsinki. Human blood was collected from voluntary healthy donors after receiving informed consent, using 
S-Monovettes containing either EDTA or LiHep as anticoagulant (Sarstedt AG and Co. KG, Nümbrecht, 
Germany). C57BL/6 mice were maintained under pathogen-free conditions in individually ventilated cages 
(IVC). All animal experiments were approved by the animal experimentation review board of the canton of 
Bern (BE138/16) and performed in compliance with the humane care and use of laboratory animals and the 
Swiss animal protection act. Mouse blood was terminally isolated from C57BL/6 J wild type mice after isoflu-
rane-induced anesthesia (Forene®, AbbVie AG, Baar, Switzerland) by periorbital sinus puncture and collected 
through Na-heparinized Micro Hematocrit-tubes (Henry Schein, Melville, NY, US) into EDTA or LiHep-coated 
Microvettes (Sarstedt AG and Co).
Reagents. Complete medium RPMI +/+ consists of RPMI 1640 supplemented with 10% FCS, Penicillin, 
Streptomycin (1/100 each) and 10 mM HEPES. RPMI 1640 Medium, Penicillin and Streptomycin were obtained 
from Biochrom (Berlin, DE). Fetal calf serum (FCS, Sera Pro, ultra-low endotoxin) and HEPES were pur-
chased from Pan Biotech (Aidenbach, DE) and Gibco®, Fischer Scientific, respectively. ABT-199 (Venetoclax) 
was obtained by BioVision (Milpitas, CA, US), ABT-263 (Navitoclax) by Selleck Chemicals (Houston, TX, US), 
WEHI-539 hydrochloride was purchased from Hycultec (Beutelsbach, DE), S63845 from ApexBio (Houston, TX, 
US). A stock solution (10 mM) of every type of used BH3-mimetics was prepared in DMSO.
Establishment of ex vivo conditions. To evaluate the impact of different types of anti-coagulants, EDTA 
and LiHep blood samples of humans and mice were diluted 1/2 in complete RPMI +/+ medium in order to 
support cell integrity. Blood samples were distributed in 96-well U-bottom tissue-culture plates (BD Falcone, 
Franklin Lakes, NJ) (200 μl/well). Samples were incubated at 37 °C, 5% CO2 for 6 h, 8 h, 16 h and 24 h without any 
Figure 3. Quantification of absolute BCL-2 molecules per cell in human and mouse lymphocytes. Shown are 
means ± SEM of absolute numbers of BCL-2 molecules per cell (ABC, antibody binding capacity) in order to 
allow inter-species comparison of human (a) and mouse (b) lymphocytes. Mouse and human blood samples 
were processed immediately after blood sampling. Gating strategy for the identification of lymphocyte subtypes 
was the same as described in Supplementary Figs. S2 and S4. A total of 3 biological replicates are shown for each 
species.
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stimuli. Afterward incubation, red blood cells of EDTA and LiHep blood samples were lysed using BD Lysing 
Solution (BD Biosciences) for 15 minutes at room temperature. Thereafter, samples were washed and resuspended 
in 600 μl Staining Buffer, which was composed of 1x PBS with 2% heat-inactivated FCS and 0.05% sodium azide 
(Merck Millipore, Zug, Switzerland). Fresh EDTA and LiHep blood samples that were immediately after blood 
withdrawal processed for flow cytometry analysis (0 h) were used as references. Data were acquired using a BD 
FACS Canto II flow cytometer (BD Bioscience).
Stimulation of LiHep blood samples with BH3-mimetics. In order to test the effect of BH3-mimetics 
on different human and mouse leukocyte populations, LiHep blood samples were diluted and distributed in 
96-well plates as mentioned above whereby mouse blood was pooled from 3–4 C57BL/6 J inbred wild type 
mice to collect enough blood for all treatment groups. Samples were exposed to medium only or to different 
BH3-mimetic compounds (ABT-199, ABT-263, WEHI-539, or S63845) all used at 1 µM, which was prepared by 
diluting the 10 mM stock solution in RPMI +/+ medium. After 8- and 16-hours incubation, mouse and human 
blood samples, respectively were processed for flow cytometric analysis.
Flow cytometric assessment of the response of blood leukocytes towards BH3-mimetics. After 
exposing to BH3-mimetics, LiHep blood samples were stained with Yellow-Green Live Cell Caspase Probe (BD 
Biosciences, San Jose, CA, US) according to manufacturer instructions. Cells were washed with 1x PBS followed 
by staining with fluorochrome-labeled antibodies (listed below) for 15 minutes at room temperature. Afterward, 
red blood cells were lysed as mentioned above. Thereafter, samples were washed and resuspended in 600 μl 
Staining Buffer. CountBrightTM absolute counting beads (Invitrogen, Basel, Switzerland) were added to the lysed 
blood samples shortly before analysis using a BD FACS Canto II flow cytometer (BD Bioscience). The following 
panels were used to identify blood leukocytes:
Human panel 1 (100 μl human blood) was used to detect basophils, eosinophils, and DCs using the follow-
ing antibodies: anti-human Lin1 FITC (clones 3G8, L27, MφP9, NCAM16.2, SJ25C1, SK7) (BD Biosciences), 
anti-human HLA-DR BV421 (clone L243), anti-human CD11c BV510 (clone 3.9), anti-human Siglec-8 PerCP/
Cy5.5 (clone 7C9), anti-human CD193 Alexa 647 (clone 5E8), anti-human CD123 PE/Cy7 (clone 6H6) all pur-
chased from BioLegend (San Diego, CA, US). Human panel 2 (50 μl human blood) was used to detect major 
human lymphocyte populations (T cells, B cells, NK cells, and NKT cells) and neutrophils. Following antibodies 
were used: anti-human CD19 BV421 (clone HIB19), anti-human CD16 BV510 (clone 3G8), anti-human CD14 
APC (clone HCD14), anti-human CD56 BV510 (clone 5.1H11), anti-human CD66b PE/Cy7 (clone G10F5) all 
from BioLegend, and anti-human CD3 FITC (clone SK7) and anti-human CD45 PerCP (clone 2D1) (both from 
BD Biosciences, Allschwil, CH). The choice of the surface antigens for the identification of the different types of 
human blood leukocytes was based on standardized gating strategies from our routine diagnostic cytomics facil-
ity at the Centre of Laboratory Medicine at the Inselspital Bern (see Supplementary Figs. S1 and S2). Mouse panel 
1 (200 μl mouse blood) was used to identify basophils, eosinophils, neutrophils and DCs using following antibod-
ies: anti-mouse IgE FITC (clone RME-1), anti-mouse CD11c BV510 (clone N418), anti-mouse CD117/c-Kit PE/
Cy7 (clone ACK2), anti-mouse Ly-6G PerCP (clone 1A8), anti-mouse CD19 APC/Cy7 (clone 6D5), anti-mouse 
NK1.1 APC/Cy7 (clone PK136), anti-mouse CD3 APC/Cy7 (clone 17A2), anti-mouse CD49b APC (clone DX5) 
(all from BioLegend), and anti-mouse CD170/Siglec F Super Bright 436 (clone 1RNM44N) (Invitrogen). Mouse 
panel 2 (100 μl mouse blood) was used to detect B cells, NK cells, NKT cells and T cells and consisted of following 
antibodies: anti-mouse CD19 BV421 (clone B4), anti-mouse CD45 PerCP (clone 30-F11), anti-mouse CD3 APC/
Cy 7 (clone 17A2), anti-mouse NK1.1 BV510 (clone PK136) anti-mouse CD14 APC (clone Sa14-2) all purchased 
from BioLegend. Gating strategies used to define mouse blood leukocytes were adapted to a great extent from 
previous studies (see Supplementary Figs. S3 and S4)19.
Detection of intracellular BCL-2 by flow cytometry. Intracellular BCL-2 expression was assessed in 
fresh EDTA blood samples of humans and mice. Surface staining of unfractionated blood samples was performed 
as mentioned above using the same antibody panels except that Yellow-Green Live Cell Caspase Probe was omit-
ted. After lysis of red blood cells, samples were washed, and 1 ml of BD Lysing Solution (BD Biosciences) was 
added in order to permeabilize the cells. Samples were incubated at 37 °C for 30 minutes. Cells were subsequently 
washed and stained with anti-BCL-2 PE (clone 124 for anti-human and clone 10C4 for anti-mouse) for 30 min-
utes at room temperature. Thereafter, samples were washed and resuspended in 600 μl Staining Buffer. In order to 
compare BCL-2 expression between human and mouse samples, absolute BCL-2 molecules per cell were deter-
mined using Quantum Simply Cellular Beads (Bangs Laboratories) according to manufacturer’s instructions. 
Briefly, the BCL-2 molecules per cell were interpolated using a standard consisting of 5 bead populations with 
increasing capacity to bind anti-BCL-2 PE through increasing levels of Fc-specific capture antibody. Subsequently, 
the signal of the PE FMO sample was subtracted from the stained samples. The results are shown as antibody 
binding capacity (ABC) per cell.
Data analysis. Raw flow cytometry data were analyzed by Flow Jo 10.5.0 (Tree Star Inc., Ashland, OR, US). 
In order to determine total cell count, raw flow cytometry data were cleaned from CountBrightTM absolute count-
ing beads (based on high fluorescence and scatter homogeneity) and doublets (based on area to height ratio of 
the forward scatter). Anucleated and non-viable cells were removed from further analysis by setting a threshold 
on low forward scatter values and events positive for Yellow-Green Live Cell Caspase Probe. Total cell count 
for each sample was calculated using CountBrightTM absolute counting beads according to the manufacturer’s 
instructions.
Statistical analysis. The alpha level was set to 0.05. Data are expressed as mean and standard deviation (SD) 
or standard error of mean (SEM) as indicated. Cell count was normalized relative to untreated control samples 
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in order to compensate for inter-donor variability. Statistical analysis of group comparison was performed using 
ordinary one-way ANOVA followed by Bonferroni’s or Dunnett’s post hoc test as indicated post hoc test using 
Prism 7 software (GraphPad, La Jolla, CA, US).
Data availability
For original data, please contact michaela.fux@insel.ch.
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 Supplementary Figure Legends 
Supplementary Figure 1. Gating strategy for the identification of human basophils, 
eosinophils, and DCs. (a) In a first step CountBright™ Absolute Counting Beads were 
excluded from further analysis based on high fluorescence in the PerCP channel. This was 
followed by the exclusion of debris, doublets, caspase positive cells, and Lin1+ cells to allow 
better cell-specific gating. (b) Basophils were identified based on low SSC, dual expression of 
CD123 and CD193 and absence of HLA-DR and CD11c. (c) Eosinophils were defined as 
SSC high, Siglec 8+, CD193+, HLA-DR- and CD11c- cells. (d) The DC population was 
summarized as pDC and mDCs due to low counts, whereby the former were identified as 
HLA-DR+, CD123+ and CD11c+ and the latter as HLA-DR+, CD123-, CD11c+. (b-d) 
Backgating of the leukocyte population (red dots) is depicted on top of all the cells that are 
negative for the Caspase Probe (blue). 
Supplementary Figure 2. Gating strategy for the identification of human lymphocytes 
(T-, B-, NK, and NKT Cells), monocytes and neutrophils. (a) To minimize background 
and fluorescence artifacts CountBright™ Absolute Counting Beads, doublets, debris, caspase 
probe+, and CD45- were excluded from further analysis. (b) T cells were identified as CD3+, 
CD19-, CD16- and CD56- (c), NKT cells were defined as CD3+, CD19-, CD16/CD56+ cells. 
(d) NK cells were defined as SSC low, CD16/56+, CD66b-, CD14-, CD3- and CD19- events. 
(e) Neutrophils were identified based on high SSC, expression of CD66b and lack of CD3 and 
CD19. (f) B cells were identified as CD19+, CD16/CD56- and CD66b-. (g) Monocytes were 
identified as CD3-, CD14+, CD19- (b-g) Backgating of the leukocyte population (red dots) is 
depicted on top of all the cells that are negative for the Caspase Probe (blue). 
Supplementary Figure 3. Gating strategy for the identification of mouse granulocytes 
(basophils, eosinophils, and neutrophils), and DCs. (a) CountBright™ Absolute Counting 
Beads, doublets, debris, caspase probe+ and cells positive for lymphocyte markers (CD3, 
CD19 and NK1.1) were excluded from further analysis. (b) Basophils were identified based 
on expression of CD49b+, IgE+ and absence of CD117, CD11c, Siglec F and Ly6G.             
(c) Eosinophil population was defined as SSC high, Siglec F+, IgE-, Ly6G-, CD11c- and 
CD117-. (d) Neutrophils were identified based on intermediate SSC and high Ly6G 
expression and lacking surface expression of Siglec F, IgE, and CD117. (e) SSC low, 
CD11c+, CD117-, CD49b-, Ly6G-, and Siglec F- population was defined as dendritic cells 
(DC). (b-e) Backgating of all leukocytes (red dots) is depicted on top of all the cells that are 
negative for the Caspase Probe (blue). 
 Supplementary Figure 4. Gating strategy for the identification of major mouse 
lymphocytes populations (T-, B-, NK, and NKT Cells) and monocytes. (a) CountBright™ 
Absolute Counting Beads, doublets, debris, caspase probe+, and CD45- events were excluded 
for all further cell-specific gating strategies. (b) T cells were identified based on low SSC, 
CD3+, CD19- and NK1.1-. (c) Except for being positive for NK1.1, NKT cells were 
identified based on the same strategy as T cells. (d) NK cells were defined as CD3-, NK1.1+, 
and CD19-. (e) B cells were defined as CD3-, CD19+, and NK1.1-. (f) Monocytes were 
defined as CD3-, CD14+ CD19-, and NK1.1- (b-e) Backgating of the leukocytes (red dots) is 
depicted on top of all the cells that are negative for the Caspase Probe (blue). 
Supplementary Figure 5. Human CD14 positive monocytes disappear spontaneously 
without the addition of BH3-mimetics within 16 hours. (a) Monocytes were defined as 
cells with intermediate SSC and high CD14 surface expression. Depicted are 4 biological 
replicates right after blood donation and after 16 hours. 
Supplementary Figure 6. Effect of different BH3-mimetics on human leukocyte 
populations after 16 hours incubation. Shown are the effect of ABT-199, ABT-263, WEHI-
539, and S63845 on total cell count of major leukocyte subpopulations in human blood 
samples (a-d). Human blood samples were kept under ex vivo culture conditions for 16h. All 
BH3-mimetics were used at a final concentration of 1 µM. The cell count of a given cell type 
in the untreated sample (dotted line) was used as a reference for normalization of the 
treatment groups. A total of 4 biological replicates are shown. Ordinary one-way ANOVA 
followed by Dunnett’s posthoc test was used for comparing control and treatment groups for 
statistical differences. Data are shown as mean (SD). n.s. (not significant); *P < 0.05; **P < 
0.01, ***P < 0.001, ****P < 0.0001.  
Supplementary Figure 7. BCL-2 expression in human and mosue lymphocytes. Shown 
are representative histograms of human (a) and mouse (b) lymphocytes. BCL-2 expression 
(gray area) within each lymphocyte subtype was compared to Fluorescence Minus One 
(FMO) control of anti-BCL-2 PE (line). 
Supplementary Figure 8. Heat map representing the main differences of the inhibition 
of BCL-2, BCL-XL, and MCL-1 between mouse and human blood leukocytes after 8 
hours incubation. (a) The magnitude of the effect of all tested BH3-mimetics was defined as 
the reciprocal value of the normalized cell count difference between treated and untreated 
samples. The magnitude of the reduction of human leukocytes was subtracted from its mouse 
 equivalent and was used to visualize the difference between both species. Resulting positive 
and negative values near 0 (black) correspond to comparable responses to a given stimulus 
between both species. Cell types that are affected to a greater extent in mouse or human blood 
are represented in green and red, respectively. Color intensity reflects the magnitude of the 
effect on cell count. (b) The P-values resulting from the ordinary one-way ANOVA group 
comparison between human and mouse leukocytes are presented in tabular form. Multiple 
comparisons were corrected with the Bonferroni’s posthoc test. P-values below the α 
significance level of 0.05 are underlined. 
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Supplementary Figure 8
a
  Adjusted P-values  
One-way ANOVA (Bonferroni) ABT-199 ABT-263 S63845 WEHI-539 
Basophils (human) vs. Basophils (mouse) 0.1835 >0.9999 >0.9999 0.0002 
Eosinophils (human) vs. Eosinophils (mouse) >0.9999 >0.9999 0.6468 <0.0001 
Neutrophils (human) vs. Neutrophils (mouse) >0.9999 >0.9999 0.057 >0.9999 
B Cells (human) vs. B Cells (mouse) 0.4274 >0.9999 >0.9999 >0.9999 
T Cells (human) vs. T Cells (mouse) 0.0002 >0.9999 >0.9999 >0.9999 
NKT Cells (human) vs. NKT Cells (mouse) <0.0001 >0.9999 >0.9999 >0.9999 
NK Cells (human) vs. NK Cells (mouse) <0.0001 0.6318 >0.9999 >0.9999 
DCs (human) vs. DCs (mouse) >0.9999 >0.9999 >0.9999 0.0078 
Monocytes (human) vs. Monocytes (mouse) >0.9999 >0.9999 >0.9999 >0.9999 
 
b
